Used in cancer therapy research, particularly targeting tumor angiogenesis. It inhibits the Delta-like ligand 4 (DLL4) pathway, which plays a key role in blood vessel formation within tumors. By blocking this pathway, it disrupts the development of tumor vasculature, leading to reduced tumor growth and metastasis in preclinical models. Investigated for use in solid tumors such as colorectal, lung, and breast cancers. Often employed as a reference in comparative studies of anti-angiogenic biologics and in the development of biosimilars or next-generation antibodies.